Peptide evidence preview
AOD-9604: evidence, mechanism, and limitations
A dose-free evidence preview of AOD-9604, including its proposed preclinical mechanism, human program, lack of established weight-loss efficacy, and regulatory context.
Direct answer
Direct answer
AOD-9604 is a synthetic fragment based on the end region of human growth hormone. Animal studies supported a fat-metabolism hypothesis, but the human development program did not establish meaningful weight-loss efficacy and was discontinued. It is not approved as a treatment for obesity or another clinical condition.
Public Evidence Passport preview
Preclinical mechanism + unsuccessful human efficacy program
Animal studies support a proposed biological mechanism, while the larger human development program did not establish a meaningful efficacy benefit for its intended weight-loss use.
- Strongest source tier
- Tier 4 — randomized controlled human program
- Editorial review
- August 4, 2026
- Source coverage
- 4 inspectable records in this public preview
What matters
- The proposed fat-metabolism mechanism comes mainly from animal work and is not confirmed as a clinically useful human pathway.
- The larger human program did not establish meaningful weight-loss efficacy.
- Published safety summaries do not establish effectiveness and include industry involvement that readers should consider.
- AOD-9604 is not approved by major North American regulators and appears on the World Anti-Doping Agency prohibited list.
Does the human evidence establish weight-loss benefits for AOD-9604?
No. The FDA's review describes a placebo-controlled obesity trial that did not meet its primary weight-loss endpoint. The company ended development for that indication.
| Source | Study design | Finding | Limit |
|---|---|---|---|
| FDA evidence review, 2024, pages 21 to 23 | FDA summary of the OPTIONS trial: double-blind and placebo-controlled, with 536 adults enrolled and 502 randomized. | No significant difference in the primary weight-loss endpoint. | The FDA relied on limited study summaries and company disclosures. This document is a regulatory review, not a full primary trial publication. |
| Stier et al., 2013 | Pooled report of safety and tolerability from the human development program. | Reports tolerability and laboratory observations. | A safety analysis does not establish weight-loss efficacy; consider the disclosed industry interests. |
Source notes updated . Added the larger trial's design and result, and distinguished the regulatory evidence review from a published primary trial report.
Mechanism
AOD-9604 is a synthetic peptide based on the C-terminal region of human growth hormone. Rodent studies reported effects on fat metabolism without the same growth-factor or glucose signals associated with the full hormone. A beta-adrenergic pathway has been proposed from animal work.
That mechanism remains a preclinical hypothesis. A pathway observed in a selected animal model does not demonstrate a meaningful effect in humans.
What the human program found
Multiple controlled human studies were conducted, including larger studies in adults with obesity. The development program did not establish a statistically meaningful weight-loss effect versus placebo and was discontinued for lack of efficacy.
A published pooled safety review described tolerability and biochemical findings from the program. It is important to separate that question from efficacy and to note the authors’ disclosed industry ties.
Claims beyond weight loss
Claims involving cartilage, joints, or broad metabolic benefit are not supported by adequate controlled human outcome trials. A mechanistic rationale or an uncontrolled signal is not a substitute for a relevant clinical comparison.
Regulatory and sport context
AOD-9604 is not approved by the U.S. Food and Drug Administration or Health Canada as a treatment. It is listed by the World Anti-Doping Agency among prohibited peptide hormones, growth factors, related substances, and mimetics. Competitive athletes should rely on current anti-doping rules and qualified sport-medicine guidance.
Inspect the record
Sources
- 01Safety and tolerability of AOD-9604 in humansJournal of Endocrinology and Metabolism
Pooled safety summary with disclosed industry interests; does not establish efficacy.
- 02U.S. Food and Drug Administration
- 03World Anti-Doping Agency
- 04PubMed
Go deeper
Carry the evidence library in your pocket.
Peptidia for iPhone adds the full reviewed library, inspectable study cards, grounded questions, and a private wellness journal—without numeric doses or protocols.